CD19-targeted chimeric antigen receptor T-cell therapies (Kymriah and Yescarta) have demonstrated impressive efficacy against B-cell lymphomas and leukemias, while oncolytic virotherapy has elicited notable responses in melanoma (Imlygic and Rigvir) and nasopharyngeal carcinoma (Oncorine) patients. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.